Electroceutical Devices Market to Surpass USD 33 Billion by 2026

The global electroceutical devices market was valued USD 17.8 billion in 2018, and is projected to exhibit a CAGR of 8.0 percent from 2018 – 2026. Electroceuticals are medical devices, which employ electrical currents to affect and modify body functions as an alternative to drug-based interventions. In contrast to pacemakers and other classical excitable-tissue stimulators, modern electroceutical devices employ sophisticated control strategies in order to modulate physiological regulation. For instance, modulation of cardiac contractility as a therapy for heart failure, modulation of gastric contractility as a therapy for diabetes, and modulation of vagus nerve traffic as a therapy for epilepsy and inflammatory diseases. Market players are actively investing in research and development to develop more efficient and innovative electroceutical devices and also retaining organic and in-organic strategies, which thereby offer lucrative opportunities in this market.

For instance, in November 2017, LivaNova PLC and MicroPort Scientific Corporation entered into a binding Letter of Intent (LOI) to sale LivaNova’s Cardiac Rhythm Management (CRM) business franchise to MicroPort for USD 190 million. Company’s CRM product portfolio includes pacemakers, high-voltage defibrillators, and cardiac resynchronization therapy devices. The acquisition helps MicroPort to add these diverse cardiac rhythm management portfolios to their existing product portfolio. In August 2014, Medtronic plc completed acquisition of Sapiens Steering Brain Stimulation (Sapiens SBS), a developer of Deep Brain Stimulation (DBS) technologies; for deal value of USD 200 million. Moreover, acquisition of Sapiens SBS strengthens Medtronic’s capabilities in modulation of brain function. Furthermore, key players are engaged in launching innovative electroceutical devices portfolio in market along with gaining regulatory approval for the same. For instance, in November 2017, Medtronic plc received US Food and Drug Administration (FDA) approval for their portfolio of Azure pacemakers with BlueSync technology, which is available in both single and dual chamber cardiac pacemakers. Company’s new Azure XT MRI and Azure S MRI pacemakers offer improved longevity, which is an estimated at 13.7 years (dual chamber).

Moreover, in November 2017, Cochlear Limited; received the USFDA approval for first remote feature to nucleus cochlear implant system thorough a telemedicine platform, which allow follow-up programming sessions. This approval is first in the artificial cochlear implant industry, benefiting various cochlear implant patients who are unable to access consistent follow-ups. Furthermore, manufacturers of implantable cardiac pacemakers are updating their product portfolio by implementing inorganic growth strategies to sustain their foothold in the market. In April 2016, Medtronic plc received USFDA approval for the world’s smallest pacemaker, the Medtronic Micra Transcatheter Pacing System (TPS). The Micra TPS is based on miniaturized pacing technology, which allows it to be delivered through a catheter and implanted directly into the heart. – Coherent Market Insights